Literature DB >> 25881117

Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.

Margaret Haney1, Divya Ramesh1,2, Andrew Glass1,3, Martina Pavlicova1,4, Gillinder Bedi1, Ziva D Cooper1.   

Abstract

Given that cannabis use is increasing in the United States, pharmacological treatment options to treat cannabis use disorder are needed. Opioid antagonists modulate cannabinoid effects and may offer a potential approach to reducing cannabis use. In this double-blind, placebo-controlled human laboratory study, we assessed the effects of naltrexone maintenance on the reinforcing, subjective, psychomotor, and cardiovascular effects of active and inactive cannabis. Nontreatment-seeking, daily cannabis smokers were randomized to receive naltrexone (50 mg: n=18 M and 5 F) or placebo (0 mg; n=26 M and 2 F) capsules for 16 days. Before, during, and after medication maintenance, participants completed 10 laboratory sessions over 4-6 weeks, assessing cannabis' behavioral and cardiovascular effects. Medication compliance was verified by observed capsule administration, plasma naltrexone, and urinary riboflavin. Relative to placebo, maintenance on naltrexone significantly reduced both active cannabis self-administration and its positive subjective effects ('good effect'). Participants in the placebo group had 7.6 times (95% CI: 1.1-51.8) the odds of self-administering active cannabis compared with the naltrexone group. This attenuation of reinforcing and positive subjective effects also influenced cannabis use in the natural ecology. Naltrexone had intrinsic effects: decreasing ratings of friendliness, food intake, and systolic blood pressure, and increasing spontaneous reports of stomach upset and headache, yet dropout rates were comparable between groups. In summary, we show for the first time that maintenance on naltrexone decreased cannabis self-administration and ratings of 'good effect' in nontreatment-seeking daily cannabis smokers. Clinical studies in patients motivated to reduce their cannabis use are warranted to evaluate naltrexone's efficacy as a treatment for cannabis use disorder.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25881117      PMCID: PMC4569951          DOI: 10.1038/npp.2015.108

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  54 in total

1.  Brief treatments for cannabis dependence: findings from a randomized multisite trial.

Authors: 
Journal:  J Consult Clin Psychol       Date:  2004-06

2.  Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.

Authors:  A M Weinstein; H Miller; I Bluvstein; E Rapoport; S Schreiber; R Bar-Hamburger; M Bloch
Journal:  Am J Drug Alcohol Abuse       Date:  2014-01       Impact factor: 3.829

3.  Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system.

Authors:  D Braida; M Pozzi; R Cavallini; M Sala
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

4.  A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.

Authors:  Barbara J Mason; Anita M Goodman; Russell M Dixon; Magdy H Hameed; Thierry Hulot; Keith Wesnes; John A Hunter; Michael G Boyeson
Journal:  Neuropsychopharmacology       Date:  2002-10       Impact factor: 7.853

5.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

6.  Adverse effects of oral naltrexone: analysis of data from two clinical trials.

Authors:  C Oncken; J Van Kirk; H R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

7.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

Review 8.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

9.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

Review 10.  Naltrexone for the treatment of obesity: review and update.

Authors:  Michael William Lee; Ken Fujioka
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

View more
  26 in total

1.  Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders.

Authors:  Simon N Katner; Kristin E Bredhold; Kevin B Steagall; Richard L Bell; Bethany S Neal-Beliveau; Mi C Cheong; Eric A Engleman
Journal:  Behav Brain Res       Date:  2019-02-22       Impact factor: 3.332

2.  Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Evan Herrmann; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin; Frances R Levin
Journal:  Addict Biol       Date:  2018-04-16       Impact factor: 4.280

Review 3.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

Review 4.  Cannabis use and cannabis use disorder.

Authors:  Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall
Journal:  Nat Rev Dis Primers       Date:  2021-02-25       Impact factor: 52.329

5.  The Problem with the Current High Potency THC Marijuana from the Perspective of an Addiction Psychiatrist.

Authors:  Elizabeth Stuyt
Journal:  Mo Med       Date:  2018 Nov-Dec

6.  Open-label pilot study of injectable naltrexone for cannabis dependence.

Authors:  Daniel P Notzon; Meredith A Kelly; C Jean Choi; Martina Pavlicova; Amy L Mahony; Daniel J Brooks; John J Mariani; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2018-02-08       Impact factor: 3.829

Review 7.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

8.  Mu-opioid antagonism in the treatment of cannabis use disorder

Authors:  Oussama Kebir; Xavier Laqueille; Fayçal Mouaffak
Journal:  J Psychiatry Neurosci       Date:  2020-03-01       Impact factor: 6.186

Review 9.  The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Authors:  Christina A Brezing; Frances R Levin
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

10.  Can Naloxone Be Used to Treat Synthetic Cannabinoid Overdose?

Authors:  Jermaine D Jones; Michelle L Nolan; Roshni Daver; Sandra D Comer; Denise Paone
Journal:  Biol Psychiatry       Date:  2016-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.